FDA removes five peptides — CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank — from Category 2 restricted compounding list
The FDA announced that AOD-9604, CJC-1295, Ipamorelin acetate, Thymosin Alpha-1, and Selank acetate were being removed from Category 2 of the agency's interim 503A bulk drug substances policy after their original safety-risk nominations were withdrawn, referring each to the Pharmacy Compounding Advisory Committee for formal review — the first procedural step toward potential compounding eligibility.
This is a summary. The reporting is U.S. Food & Drug Administration's, and the link below goes to the original article.